Global Genomics in Cancer Care Market - 2025 -2033
Genomics in Cancer Care Market Size& Industry Outlook
The global genomics in cancer care market size reached US$ 16.14billion with rise of US$18.6billion in 2024 is expected to reach US$ 72.87billion by 2033, growing at a CAGR of 16.8%during the forecast period 2025-2033.
One of the major drivers of the global genomics in cancer care market is the growing integration of liquid biopsy technologies for early cancer detection and monitoring. Liquid biopsies, which analyze circulating tumor DNA (ctDNA) or other biomarkers from a simple blood sample, offer a non-invasive, cost-effective, and rapid alternative to traditional tissue biopsies. For instance, companies like Guardant Health and Foundation Medicine are advancing liquid biopsy platforms that enable early detection of cancers, continuous disease monitoring, and assessment of treatment response. This technology is gaining significant traction in clinical practice as it improves patient outcomes, reduces diagnostic delays, and supports the shift toward minimally invasive approaches in oncology.
Key Highlights
Drivers: Rising adoption of next-generation sequencing (NGS) in oncology diagnostics is significantly driving the genomics in cancer care market growth
The rising adoption of Next-Generation Sequencing (NGS) in oncology diagnostics is playing a transformative role in driving the global genomics in cancer care market, as it allows for a far deeper and more precise understanding of the genetic underpinnings of cancer. Unlike traditional methods, NGS can analyze hundreds to thousands of genes simultaneously, making it possible to detect a wide spectrum of mutations, including single nucleotide variants, insertions, deletions, copy number alterations, and gene fusions, all in a single test. This comprehensive profiling enables oncologists to identify actionable mutations and design highly targeted treatment strategies, significantly improving patient outcomes
For instance, in July 2025, Illumina Inc. has unveiled the latest version of its flagship cancer research assay, TruSight Oncology 500 v2, designed to deliver comprehensive genomic profiling (CGP). CGP plays a vital role in advancing precision medicine by generating detailed molecular tumor profiles that support research in therapy selection and clinical trial matching. The upgraded TSO 500 v2 provides an enhanced, streamlined sample-to-analysis workflow, underscoring Illumina’s commitment to offering researchers and laboratories high-quality, rigorously validated solutions for oncology research.
Restraints: Limited reimbursement policies and regulatory challenges are hampering the growth of the genomics in cancer care market
The global genomics in cancer care market faces significant barriers due to limited reimbursement policies and regulatory challenges. Despite technological advancements, genomic tests like next-generation sequencing and comprehensive genomic profiling remain expensive and lack standardized reimbursement frameworks. This restricts patient access, especially in emerging markets. The U.S. Centers for Medicare & Medicaid Services has approved coverage for certain FDA-approved NGS-based companion diagnostics, but similar support is inconsistent in European and Asia-Pacific regions. Regulatory complexities also hinder innovation and commercialization, restraining the genomics in cancer care market's growth potential.
Segmentation Analysis
The global genomics in cancer care market is segmented based on product type, technology, application, end user, and region.
Product Type:
The instruments from product type segment to dominate the genomics in cancer care market with a 54.1% share in 2024
The instruments segment is driven by the increasing demand for advanced platforms that enable high-throughput genomic analysis and efficient cancer research. Rising investments by hospitals, diagnostic centers, and research institutions in state-of-the-art sequencers, PCR systems, and microarrays are boosting adoption. Continuous innovations, such as automated sample preparation systems and integrated sequencing platforms, are enhancing accuracy, reducing turnaround time, and improving ease of use. Additionally, the growing prevalence of cancer and the need for rapid, precise diagnostics are pushing healthcare providers to adopt robust instruments that support large-scale genomic studies and routine clinical testing.
For instance, in September 2025, MGI Tech Co., Ltd. has launched the DNBSEQ-T7+, a high-throughput sequencer designed for large-scale genomic research. The T7+ delivers over 14 Tb/day of data in 24 hours, offering a smaller footprint, flexible run configurations, and end-to-end automation. Known as a 'data mining machine,' it redefines high-throughput sequencing by combining daily output with ease of use and multi-omics versatility.
Technology:
The next generation sequencing segment is estimated to have a 41.2% of the genomics in cancer care market share in 2024
The NGS segment is propelled by its ability to provide comprehensive genomic profiling, enabling the detection of multiple genetic alterations simultaneously for precision oncology. Its applications in therapy selection, prognosis, and minimal residual disease monitoring make it indispensable in cancer care.
Increasing clinical adoption of NGS-based companion diagnostics, along with regulatory approvals for tests like Illumina’s TruSight Oncology 500 and Thermo Fisher’s Oncomine Dx, is further accelerating growth. Declining sequencing costs, coupled with rising awareness of the role of genomics in personalized cancer treatment, are also major factors driving adoption. Moreover, government initiatives and funding support for genomics-based cancer research continue to strengthen the NGS segment’s position in the market.
Geographical Analysis
North America dominates the global genomics in cancer care market with a 42.5% in 2024
The market in North America is primarily driven by well-established healthcare infrastructure, widespread adoption of next-generation sequencing (NGS), and high investment levels from biotechnology and pharmaceutical companies. Favorable reimbursement frameworks, particularly for FDA-approved companion diagnostics, along with strong clinical research networks, further accelerate the integration of genomic testing in oncology. The presence of major players like Illumina, Thermo Fisher Scientific, and Guardant Health also strengthens regional growth.
In the U.S., the market is propelled by rising cancer prevalence, regulatory support from agencies like the FDA for genomic-based diagnostics, and strong reimbursement coverage for certain NGS tests under the Centers for Medicare & Medicaid Services (CMS). Additionally, the U.S. leads in clinical trials for targeted therapies and immunotherapies that require genomic profiling, boosting demand for advanced diagnostic assays and instruments.
For instance, in July 2025, NIST and other institutions have released extensive data on the genome of pancreatic cancer cells, enabling researchers, clinical labs, and drug and biotech companies to study cancer genes and develop lifesaving therapies, making this the first cancer cell line developed from an individual's consent.
Europe is the second region after North America which is expected to dominate the global genomics in cancer care market with a 34.5% in 2024
Growth in Europe is supported by government-backed precision medicine initiatives, increasing adoption of comprehensive genomic profiling in oncology, and collaborative efforts between research institutions and healthcare systems. Countries like Germany and France are investing heavily in integrating genomics into cancer care, while the EU’s focus on cross-border research programs is helping build advanced genomic networks.
The UK market benefits from strong government policies, including the NHS Genomic Medicine Service, which provides broad patient access to genomic testing. High cancer incidence rates, coupled with initiatives like the 100,000 Genomes Project, have positioned the UK as a leader in implementing large-scale genomic data for cancer research and patient care. Partnerships between academia, healthcare providers, and diagnostic companies are further fueling adoption.
The Asia Pacific region is the fastest-growing region in the global genomics in cancer care market, with a CAGR of 7.1% in 2024
The Asia-Pacific market is expanding rapidly due to rising cancer burden, improving healthcare infrastructure, and increasing government investments in genomic medicine. Countries such as China, India, and South Korea are driving growth through large-scale genome sequencing projects and partnerships with global players. The growing availability of cost-effective sequencing technologies is also encouraging adoption in clinical oncology settings.
Japan is a frontrunner in the region, driven by government-backed cancer genomic medicine programs and a supportive regulatory framework for NGS-based diagnostics. High awareness among clinicians, integration of genomic profiling in national healthcare guidelines, and early adoption of advanced sequencing platforms have positioned Japan as a key hub for precision oncology.
For instance, in May 2025, Illumina's TruSight Oncology Comprehensive assay has been approved by Japan's Ministry of Health, Labour and Welfare, as a Class III/IV Medical Device in Japan.
Competitive Landscape
Top companies in the genomics in cancer care market include Illumina, Thermos Fisher Scientific, BGI Genomics, QIAGEN, Roche Diagnostics, Guardant Health, Natera, Myriad Genetics and among others.
Illumina: Illumina is a leading provider of next-generation sequencing platforms and comprehensive genomic profiling (CGP) assays, enabling clinicians and researchers to analyze hundreds of cancer-related genes simultaneously. Its sequencing systems, including NovaSeq and NextSeq, are widely used in hospitals, diagnostic labs, and research institutions worldwide. Illumina has secured regulatory approvals in key markets like the U.S., Europe, and Japan, and has formed partnerships with pharmaceutical companies for companion diagnostics. Its continuous innovations in high-throughput sequencing, automation, and bioinformatics drive the growth of the cancer genomics market globally.
Key Developments:
The global genomics in cancer care market size reached US$ 16.14billion with rise of US$18.6billion in 2024 is expected to reach US$ 72.87billion by 2033, growing at a CAGR of 16.8%during the forecast period 2025-2033.
One of the major drivers of the global genomics in cancer care market is the growing integration of liquid biopsy technologies for early cancer detection and monitoring. Liquid biopsies, which analyze circulating tumor DNA (ctDNA) or other biomarkers from a simple blood sample, offer a non-invasive, cost-effective, and rapid alternative to traditional tissue biopsies. For instance, companies like Guardant Health and Foundation Medicine are advancing liquid biopsy platforms that enable early detection of cancers, continuous disease monitoring, and assessment of treatment response. This technology is gaining significant traction in clinical practice as it improves patient outcomes, reduces diagnostic delays, and supports the shift toward minimally invasive approaches in oncology.
Key Highlights
- North America dominates the genomics in cancer care market with the largest revenue share of 42.5% in 2024.
- The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of7.1% over the forecast period.
- Based on product type, instruments segmented the market with the largest revenue share of 54.1% in 2024.
- The major market players in the Illumina, Thermo Fisher Scientific, BGI Genomics, QIAGEN, Roche Diagnostics, Guardant Health, Natera, Myriad Geneticsand among others.
Drivers: Rising adoption of next-generation sequencing (NGS) in oncology diagnostics is significantly driving the genomics in cancer care market growth
The rising adoption of Next-Generation Sequencing (NGS) in oncology diagnostics is playing a transformative role in driving the global genomics in cancer care market, as it allows for a far deeper and more precise understanding of the genetic underpinnings of cancer. Unlike traditional methods, NGS can analyze hundreds to thousands of genes simultaneously, making it possible to detect a wide spectrum of mutations, including single nucleotide variants, insertions, deletions, copy number alterations, and gene fusions, all in a single test. This comprehensive profiling enables oncologists to identify actionable mutations and design highly targeted treatment strategies, significantly improving patient outcomes
For instance, in July 2025, Illumina Inc. has unveiled the latest version of its flagship cancer research assay, TruSight Oncology 500 v2, designed to deliver comprehensive genomic profiling (CGP). CGP plays a vital role in advancing precision medicine by generating detailed molecular tumor profiles that support research in therapy selection and clinical trial matching. The upgraded TSO 500 v2 provides an enhanced, streamlined sample-to-analysis workflow, underscoring Illumina’s commitment to offering researchers and laboratories high-quality, rigorously validated solutions for oncology research.
Restraints: Limited reimbursement policies and regulatory challenges are hampering the growth of the genomics in cancer care market
The global genomics in cancer care market faces significant barriers due to limited reimbursement policies and regulatory challenges. Despite technological advancements, genomic tests like next-generation sequencing and comprehensive genomic profiling remain expensive and lack standardized reimbursement frameworks. This restricts patient access, especially in emerging markets. The U.S. Centers for Medicare & Medicaid Services has approved coverage for certain FDA-approved NGS-based companion diagnostics, but similar support is inconsistent in European and Asia-Pacific regions. Regulatory complexities also hinder innovation and commercialization, restraining the genomics in cancer care market's growth potential.
Segmentation Analysis
The global genomics in cancer care market is segmented based on product type, technology, application, end user, and region.
Product Type:
The instruments from product type segment to dominate the genomics in cancer care market with a 54.1% share in 2024
The instruments segment is driven by the increasing demand for advanced platforms that enable high-throughput genomic analysis and efficient cancer research. Rising investments by hospitals, diagnostic centers, and research institutions in state-of-the-art sequencers, PCR systems, and microarrays are boosting adoption. Continuous innovations, such as automated sample preparation systems and integrated sequencing platforms, are enhancing accuracy, reducing turnaround time, and improving ease of use. Additionally, the growing prevalence of cancer and the need for rapid, precise diagnostics are pushing healthcare providers to adopt robust instruments that support large-scale genomic studies and routine clinical testing.
For instance, in September 2025, MGI Tech Co., Ltd. has launched the DNBSEQ-T7+, a high-throughput sequencer designed for large-scale genomic research. The T7+ delivers over 14 Tb/day of data in 24 hours, offering a smaller footprint, flexible run configurations, and end-to-end automation. Known as a 'data mining machine,' it redefines high-throughput sequencing by combining daily output with ease of use and multi-omics versatility.
Technology:
The next generation sequencing segment is estimated to have a 41.2% of the genomics in cancer care market share in 2024
The NGS segment is propelled by its ability to provide comprehensive genomic profiling, enabling the detection of multiple genetic alterations simultaneously for precision oncology. Its applications in therapy selection, prognosis, and minimal residual disease monitoring make it indispensable in cancer care.
Increasing clinical adoption of NGS-based companion diagnostics, along with regulatory approvals for tests like Illumina’s TruSight Oncology 500 and Thermo Fisher’s Oncomine Dx, is further accelerating growth. Declining sequencing costs, coupled with rising awareness of the role of genomics in personalized cancer treatment, are also major factors driving adoption. Moreover, government initiatives and funding support for genomics-based cancer research continue to strengthen the NGS segment’s position in the market.
Geographical Analysis
North America dominates the global genomics in cancer care market with a 42.5% in 2024
The market in North America is primarily driven by well-established healthcare infrastructure, widespread adoption of next-generation sequencing (NGS), and high investment levels from biotechnology and pharmaceutical companies. Favorable reimbursement frameworks, particularly for FDA-approved companion diagnostics, along with strong clinical research networks, further accelerate the integration of genomic testing in oncology. The presence of major players like Illumina, Thermo Fisher Scientific, and Guardant Health also strengthens regional growth.
In the U.S., the market is propelled by rising cancer prevalence, regulatory support from agencies like the FDA for genomic-based diagnostics, and strong reimbursement coverage for certain NGS tests under the Centers for Medicare & Medicaid Services (CMS). Additionally, the U.S. leads in clinical trials for targeted therapies and immunotherapies that require genomic profiling, boosting demand for advanced diagnostic assays and instruments.
For instance, in July 2025, NIST and other institutions have released extensive data on the genome of pancreatic cancer cells, enabling researchers, clinical labs, and drug and biotech companies to study cancer genes and develop lifesaving therapies, making this the first cancer cell line developed from an individual's consent.
Europe is the second region after North America which is expected to dominate the global genomics in cancer care market with a 34.5% in 2024
Growth in Europe is supported by government-backed precision medicine initiatives, increasing adoption of comprehensive genomic profiling in oncology, and collaborative efforts between research institutions and healthcare systems. Countries like Germany and France are investing heavily in integrating genomics into cancer care, while the EU’s focus on cross-border research programs is helping build advanced genomic networks.
The UK market benefits from strong government policies, including the NHS Genomic Medicine Service, which provides broad patient access to genomic testing. High cancer incidence rates, coupled with initiatives like the 100,000 Genomes Project, have positioned the UK as a leader in implementing large-scale genomic data for cancer research and patient care. Partnerships between academia, healthcare providers, and diagnostic companies are further fueling adoption.
The Asia Pacific region is the fastest-growing region in the global genomics in cancer care market, with a CAGR of 7.1% in 2024
The Asia-Pacific market is expanding rapidly due to rising cancer burden, improving healthcare infrastructure, and increasing government investments in genomic medicine. Countries such as China, India, and South Korea are driving growth through large-scale genome sequencing projects and partnerships with global players. The growing availability of cost-effective sequencing technologies is also encouraging adoption in clinical oncology settings.
Japan is a frontrunner in the region, driven by government-backed cancer genomic medicine programs and a supportive regulatory framework for NGS-based diagnostics. High awareness among clinicians, integration of genomic profiling in national healthcare guidelines, and early adoption of advanced sequencing platforms have positioned Japan as a key hub for precision oncology.
For instance, in May 2025, Illumina's TruSight Oncology Comprehensive assay has been approved by Japan's Ministry of Health, Labour and Welfare, as a Class III/IV Medical Device in Japan.
Competitive Landscape
Top companies in the genomics in cancer care market include Illumina, Thermos Fisher Scientific, BGI Genomics, QIAGEN, Roche Diagnostics, Guardant Health, Natera, Myriad Genetics and among others.
Illumina: Illumina is a leading provider of next-generation sequencing platforms and comprehensive genomic profiling (CGP) assays, enabling clinicians and researchers to analyze hundreds of cancer-related genes simultaneously. Its sequencing systems, including NovaSeq and NextSeq, are widely used in hospitals, diagnostic labs, and research institutions worldwide. Illumina has secured regulatory approvals in key markets like the U.S., Europe, and Japan, and has formed partnerships with pharmaceutical companies for companion diagnostics. Its continuous innovations in high-throughput sequencing, automation, and bioinformatics drive the growth of the cancer genomics market globally.
Key Developments:
- In September 2025, The Hyundai Motor India Foundation (HMIF) and IIT Madras have launched 'Hyundai Hope for Cancer', a program aimed at improving pediatric cancer care in India. The initiative includes the Hyundai Center for Cancer Genomics at IIT Madras, Chennai.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Technology
2.5. Snippet by Application
2.6. Snippet byEnd User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Adoption of Next-Generation Sequencing (NGS) in Oncology Diagnostics
3.1.1.2. Increasing Demand for Precision Medicine and Companion Diagnostics
3.1.2. Restraints
3.1.2.1. High Cost of Genomic Testing and Infrastructure Requirements
3.1.2.2. Limited Reimbursement Policies and Regulatory Challenges
3.1.3. Opportunity
3.1.3.1. Expansion of Liquid Biopsy and Minimal Residual Disease (MRD) Testing
3.1.3.2. Growing Integration of Genomics in Multi-Cancer Early Detection Programs
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. GENOMICS IN CANCER CARE MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
6. GENOMICS IN CANCER CARE MARKET, BY TECHNOLOGY
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index, By Technology
6.2. Next Generation Sequencing*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. PCR
6.4. Microarrays
6.5. Nuclei Acid Extraction and Purification
6.6. Others
7. GENOMICS IN CANCER CARE MARKET, BY APPLICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Diagnostics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Personalized Medicine
7.4. Drug Discovery & Development
8. GENOMICS IN CANCER CARE MARKET, BY END USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals & Oncology Clinics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Labs
8.4. Academic & Research Centers
8.5. Pharma & CROs
9. GENOMICS IN CANCER CARE MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Illumina*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Thermo Fisher Scientific
11.3. BGI Genomics
11.4. QIAGEN
11.5. Roche Diagnostics
11.6. Guardant Health
11.7. Natera
11.8. Myriad Genetics ( LIST NOT EXHAUSTIVE )
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Technology
2.5. Snippet by Application
2.6. Snippet byEnd User
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Adoption of Next-Generation Sequencing (NGS) in Oncology Diagnostics
3.1.1.2. Increasing Demand for Precision Medicine and Companion Diagnostics
3.1.2. Restraints
3.1.2.1. High Cost of Genomic Testing and Infrastructure Requirements
3.1.2.2. Limited Reimbursement Policies and Regulatory Challenges
3.1.3. Opportunity
3.1.3.1. Expansion of Liquid Biopsy and Minimal Residual Disease (MRD) Testing
3.1.3.2. Growing Integration of Genomics in Multi-Cancer Early Detection Programs
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. GENOMICS IN CANCER CARE MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Instruments*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Consumables
6. GENOMICS IN CANCER CARE MARKET, BY TECHNOLOGY
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
6.1.2. Market Attractiveness Index, By Technology
6.2. Next Generation Sequencing*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. PCR
6.4. Microarrays
6.5. Nuclei Acid Extraction and Purification
6.6. Others
7. GENOMICS IN CANCER CARE MARKET, BY APPLICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Diagnostics*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Personalized Medicine
7.4. Drug Discovery & Development
8. GENOMICS IN CANCER CARE MARKET, BY END USER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals & Oncology Clinics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnostic Labs
8.4. Academic & Research Centers
8.5. Pharma & CROs
9. GENOMICS IN CANCER CARE MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Illumina*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Thermo Fisher Scientific
11.3. BGI Genomics
11.4. QIAGEN
11.5. Roche Diagnostics
11.6. Guardant Health
11.7. Natera
11.8. Myriad Genetics ( LIST NOT EXHAUSTIVE )
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Genomics in Cancer Care Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Genomics in Cancer Care Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Genomics in Cancer Care Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Genomics in Cancer Care Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Genomics in Cancer Care Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Genomics in Cancer Care Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Genomics in Cancer Care Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 10 Global Genomics in Cancer Care Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 Global Genomics in Cancer Care Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 14 Global Genomics in Cancer Care Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Genomics in Cancer Care Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 18 North America Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 North America Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 North America Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Europe Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 23 Europe Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Europe Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 25 Europe Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 33 South America Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 South America Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 35 South America Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Illumina: Overview
Table 42 Illumina: Product Portfolio
Table 43 Illumina: Key Developments
Table 44 Thermo Fisher Scientific: Overview
Table 45 Thermo Fisher Scientific: Product Portfolio
Table 46 Thermo Fisher Scientific: Key Developments
Table 47 BGI Genomics: Overview
Table 48 BGI Genomics: Product Portfolio
Table 49 BGI Genomics: Key Developments
Table 50 QIAGEN: Overview
Table 51 QIAGEN: Product Portfolio
Table 52 QIAGEN: Key Developments
Table 53 Roche Diagnostics: Overview
Table 54 Roche Diagnostics: Product Portfolio
Table 55 Roche Diagnostics: Key Developments
Table 56 Guardant Health: Overview
Table 57 Guardant Health: Product Portfolio
Table 58 Guardant Health: Key Developments
Table 59 Natera: Overview
Table 60 Natera: Product Portfolio
Table 61 Natera: Key Developments
Table 62 Myriad Genetics: Overview
Table 63 Myriad Genetics: Product Portfolio
Table 64 Myriad Genetics: Key Developments
Table 1 Global Genomics in Cancer Care Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Genomics in Cancer Care Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Genomics in Cancer Care Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Genomics in Cancer Care Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Genomics in Cancer Care Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Genomics in Cancer Care Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 8 Global Genomics in Cancer Care Market Value, By Technology, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 10 Global Genomics in Cancer Care Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 12 Global Genomics in Cancer Care Market Value, By End User, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 14 Global Genomics in Cancer Care Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Genomics in Cancer Care Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 17 North America Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 18 North America Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 19 North America Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 20 North America Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Europe Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 23 Europe Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 24 Europe Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 25 Europe Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 29 Asia-Pacific Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 30 Asia-Pacific Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 32 South America Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 33 South America Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 34 South America Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 35 South America Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Genomics in Cancer Care Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Genomics in Cancer Care Market Value, By Technology, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Genomics in Cancer Care Market Value, By Application, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Genomics in Cancer Care Market Value, By End User, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Genomics in Cancer Care Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Illumina: Overview
Table 42 Illumina: Product Portfolio
Table 43 Illumina: Key Developments
Table 44 Thermo Fisher Scientific: Overview
Table 45 Thermo Fisher Scientific: Product Portfolio
Table 46 Thermo Fisher Scientific: Key Developments
Table 47 BGI Genomics: Overview
Table 48 BGI Genomics: Product Portfolio
Table 49 BGI Genomics: Key Developments
Table 50 QIAGEN: Overview
Table 51 QIAGEN: Product Portfolio
Table 52 QIAGEN: Key Developments
Table 53 Roche Diagnostics: Overview
Table 54 Roche Diagnostics: Product Portfolio
Table 55 Roche Diagnostics: Key Developments
Table 56 Guardant Health: Overview
Table 57 Guardant Health: Product Portfolio
Table 58 Guardant Health: Key Developments
Table 59 Natera: Overview
Table 60 Natera: Product Portfolio
Table 61 Natera: Key Developments
Table 62 Myriad Genetics: Overview
Table 63 Myriad Genetics: Product Portfolio
Table 64 Myriad Genetics: Key Developments
LIST OF FIGURES
Figure 1 Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 4 Global Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 6 Global Genomics in Cancer Care Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Genomics in Cancer Care Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Instruments Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 9 Consumables Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Genomics in Cancer Care Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 11 Next Generation Sequencing Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 12 PCR Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 13 Microarrays Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 14 Nuclei Acid Extraction and Purification Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Genomics in Cancer Care Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 17 Diagnostics Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 18 Personalized Medicine Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 19 Drug Discovery & Development Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Genomics in Cancer Care Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 21 Hospitals & Oncology Clinics End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 22 Diagnostic Labs End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 23 Academic & Research Centers End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 24 Pharma & CROs End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Genomics in Cancer Care Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 28 North America Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 29 North America Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 30 North America Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 31 North America Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)
Figure 32 Europe Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 33 Europe Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 34 Europe Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 35 Europe Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 36 Europe Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 37 Europe Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)
Figure 38 Asia-Pacific Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 39 Asia-Pacific Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 40 Asia-Pacific Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 41 Asia-Pacific Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 42 Asia-Pacific Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 43 Asia-Pacific Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)
Figure 44 South America Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 45 South America Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 46 South America Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 47 South America Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 48 South America Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 49 South America Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)
Figure 50 Middle East and Africa Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 51 Middle East and Africa Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 52 Middle East and Africa Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 53 Middle East and Africa Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 54 Middle East and Africa Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 55 Illumina: Financials
Figure 56 Thermo Fisher Scientific: Financials
Figure 57 BGI Genomics: Financials
Figure 58 QIAGEN: Financials
Figure 59 Roche Diagnostics: Financials
Figure 60 Guardant Health: Financials
Figure 61 Natera: Financials
Figure 62 Myriad Genetics: Financials
Figure 1 Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 4 Global Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 5 Global Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 6 Global Genomics in Cancer Care Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Genomics in Cancer Care Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 8 Instruments Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 9 Consumables Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 10 Global Genomics in Cancer Care Market Y-o-Y Growth, By Technology, 2023-2033 (%)
Figure 11 Next Generation Sequencing Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 12 PCR Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 13 Microarrays Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 14 Nuclei Acid Extraction and Purification Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Technology in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Genomics in Cancer Care Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 17 Diagnostics Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 18 Personalized Medicine Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 19 Drug Discovery & Development Application in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Genomics in Cancer Care Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 21 Hospitals & Oncology Clinics End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 22 Diagnostic Labs End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 23 Academic & Research Centers End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 24 Pharma & CROs End User in Global Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 25 Global Genomics in Cancer Care Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 26 North America Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 27 North America Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 28 North America Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 29 North America Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 30 North America Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 31 North America Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)
Figure 32 Europe Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 33 Europe Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 34 Europe Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 35 Europe Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 36 Europe Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 37 Europe Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)
Figure 38 Asia-Pacific Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 39 Asia-Pacific Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 40 Asia-Pacific Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 41 Asia-Pacific Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 42 Asia-Pacific Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 43 Asia-Pacific Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)
Figure 44 South America Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 45 South America Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 46 South America Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 47 South America Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 48 South America Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 49 South America Genomics in Cancer Care Market Share, By Country, 2024 & 2033 (%)
Figure 50 Middle East and Africa Genomics in Cancer Care Market Value, 2022-2033 (US$ Billion)
Figure 51 Middle East and Africa Genomics in Cancer Care Market Share, By Product Type, 2024 & 2033 (%)
Figure 52 Middle East and Africa Genomics in Cancer Care Market Share, By Technology, 2024 & 2033 (%)
Figure 53 Middle East and Africa Genomics in Cancer Care Market Share, By Application, 2024 & 2033 (%)
Figure 54 Middle East and Africa Genomics in Cancer Care Market Share, By End User, 2024 & 2033 (%)
Figure 55 Illumina: Financials
Figure 56 Thermo Fisher Scientific: Financials
Figure 57 BGI Genomics: Financials
Figure 58 QIAGEN: Financials
Figure 59 Roche Diagnostics: Financials
Figure 60 Guardant Health: Financials
Figure 61 Natera: Financials
Figure 62 Myriad Genetics: Financials
